**5. Conclusion**

The management of the TNBC is the interesting among all cases with breast carcinoma. As TNBC has higher chances of disease relapse, metastasis, and limited survival. The documentation of markers in near future will support the management guidelines in TNBC remains a clinically indolent. Immunotherapy acts in ICIs, promises the pronounced outcomes by immunotherapy agent (ATEZOLIZUMAB). As with unlimited hope and confidence that future ongoing research studies will add more understanding of the progression of the TNBC and will enhance the options for the management that leads towards the better survival.

Novel management options have offered the hope for the improved survival with better outcome by the upcoming period.
